Drug-Induced Pulmonary Fibrosis: National Database Analysis

Drug-Induced Pulmonary Fibrosis: National Database Analysis

Background/Objectives: Pulmonary fibrosis (PF) results in a progressive decline of lung function due to scarring. Drugs are among the most common causes of PF. The objective of our study was to reveal the structure of drugs involved in PF development. Methods: we performed a retrospective descriptiv...

Full description

Saved in:

Bibliographic Details
Main Authors:	Olga I. Butranova, Elizaveta N. Terekhina, Sergey K. Zyryanov, Geliia N. Gildeeva, Anna A. Abramova, Yury O. Kustov, Irina L. Asetskaya, Vitaly A. Polivanov
Format:	Article
Language:	English
Published:	MDPI AG 2024-11-01
Series:	Biomedicines
Subjects:	drug-induced pulmonary fibrosis pharmacovigilance adverse drug reactions antineoplastic and immunomodulating agents rituximab
Online Access:	https://www.mdpi.com/2227-9059/12/12/2650
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The role of circRNA in breast cancer drug resistance
by: Shaofeng Yang, et al.
Published: (2024-12-01)

Real-world pharmacovigilance study of drug-induced autoimmune hepatitis from the FAERS database
by: Bu-kun Zhu, et al.
Published: (2025-02-01)

Observational study of drug-drug interactions in oncological inpatients
by: María Sacramento Díaz-Carrasco, et al.
Published: (2018-01-01)

A comparative study of contamination in three closed systems for the preparation of hazardous drugs through simulations with fluorescein
by: Eva González-Haba-Peña, et al.
Published: (2018-11-01)

Navigating Recent Changes in Dosing Information: Dynamics of FDA‐Approved Monoclonal Antibodies in Post‐Marketing Realities
by: Nai Lee, et al.
Published: (2025-01-01)

Comparative study of preparation of hazardous drugs with different closed-system drug transfer devices by means of simulation with fluorescein
by: Eva González-Haba Peña, et al.
Published: (2016-12-01)

Off-label use of oncology drugs: national survey results
by: Eva González-Haba Peña, et al.
Published: (2015-09-01)

Development and design of the BELpREG registration system for the collection of real-world data on medication use in pregnancy and mother-infant outcomes
by: Laure Sillis, et al.
Published: (2023-05-01)

A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases
by: Qian Liu, et al.
Published: (2024-11-01)

An Assessment of Surface Contamination and Dermal Exposure to 5-Fluorouracil in Healthcare Settings by UPLC-MS/MS Using a New Atmospheric Pressure Ionization Source
by: Matteo Creta, et al.
Published: (2024-10-01)

Hazardous drugs levels in compounding area surfaces of Hospital Pharmacies Services: multicentric study
by: José Luis Poveda-Andrés, et al.
Published: (2018-07-01)

Monitoring contamination of hazardous drug compounding surfaces at hospital pharmacy departments. A consensus Statement. Practice guidelines of the Spanish Society of Hospital Pharmacists (SEFH)
by: Silvia Valero-García, et al.
Published: (2021-03-01)

Degree of technological implementation in intravenous chemotherapy management in hospitals of the Autonomous Community of Madrid
by: Silvia Peña-Cabia, et al.
Published: (2017-07-01)

PHARMACOVİGİLANCE OF DRUG-INDUCED LEUKEMİA: A DESCRİPTİVE STUDY OF FDA ADVERSE EVENT REPORTİNG SYSTEM FROM 1969-2024
by: Ahmet Sarici, et al.
Published: (2024-12-01)

Uncovering the Complexities of Drug Bans in India: Are Key Considerations Being Overlooked?
by: Samiksha Bhattacharjee, et al.
Published: (2024-11-01)

Recent development of micro-nano carriers for oral antineoplastic drug delivery
by: Hongzheng Li, et al.
Published: (2025-02-01)

Safety assessment of tolvaptan: real-world adverse event analysis using the FAERS database
by: Peiyang Cao, et al.
Published: (2025-01-01)

Analyzing the adverse events of NK-1 receptor antagonists: a pharmacovigilance study from the FAERS database
by: Hong Pan, et al.
Published: (2024-12-01)

Barriers to and facilitators of healthcare professionals in ADR reporting in a tertiary care hospital in India
by: Ian Osoro N, et al.
Published: (2025-01-01)

Use of oral antineoplastic in special situations in a third level hospital: real life results
by: José Miguel Ferrari-Piquero, et al.
Published: (2018-01-01)

A guide for the administration of oral antineoplastic in patients with swallowing disorders
by: Eduardo Tejedor-Tejada, et al.
Published: (2021-05-01)

Immunomodulating Treatment of Multiple Sclerosis — the Tasks and Role of a Neurological Nurse
by: Anna Smelkowska, et al.
Published: (2018-06-01)

Integrating pharmacovigilance into the routine of pharmacy department: experience of nine years
by: Ariadna Pérez-Ricart, et al.
Published: (2019-07-01)

Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis
by: D. V. Garbuzenko
Published: (2022-01-01)

Hospital medication errors in a pharmacovigilance system in Colombia
by: Jorge Enrique Machado-Alba, et al.
Published: (2015-11-01)

Reversible cerebral vasoconstriction syndrome in a methylphenidate-treated patient: a case report
by: Marie-Noëlle Osmont, et al.
Published: (2024-12-01)

Spontaneous adverse drug reactions reported in a thirteen-year pharmacovigilance program in a tertiary university hospital
by: E. Montané, et al.
Published: (2024-12-01)

Enhancing ovarian cancer treatment: Synergistic effects of methotrexate (Methotrexate)- and quercetin-loaded chitosan nanoparticles
by: Hamed Dadashi, et al.
Published: (2024-12-01)

Real world pharmacovigilance assessment of drug related macular degeneration risks
by: Xiaodong Chen, et al.
Published: (2025-01-01)

BABINE: An original and user-friendly scale for the simple and quick management of herb-drug interactions in clinical practice
by: Anthony Cnudde, et al.
Published: (2024-12-01)

Improving ADR reporting in Jordan: a qualitative exploration of pharmacists’ perspectives
by: Amal K. Suleiman
Published: (2025-01-01)

Comparative Analysis of Adverse Drug Reactions Associated with Fluoroquinolones and Other Antibiotics: A Retrospective Pharmacovigilance Study
by: Alshareef H, et al.
Published: (2025-02-01)

Influence of differential source patterns in the detection of signals of disproportionate reporting for PARP inhibitors
by: Jordi Mestres, et al.
Published: (2024-12-01)

The readiness of the spontaneous reporting system for COVID-19 vaccines safety monitoring in Croatia
by: Kovačić Barbara, et al.
Published: (2023-06-01)

A Comprehensive 10-Year Nationwide Pharmacovigilance Surveillance on Antibacterial Agents in Korea: Data Mining for Signal Detection of Trends and Seriousness of Adverse Events
by: Seon Hu Mo, et al.
Published: (2025-01-01)

Medicines under additional monitoring in the European Union
by: Esther Salgueiro, et al.
Published: (2019-01-01)

A New Era of Pharmacovigilance: Future Challenges and Opportunities
by: Gianluca Trifirò, et al.
Published: (2022-02-01)

Incidence, characteristics, and clinical impact of serious adverse events in patients with breast cancer receiving antineoplastic treatment in the ambulatory setting
by: Zahieh AbuAloush, et al.
Published: (2024-12-01)

DTA Atlas: A massive-scale drug repurposing database
by: Madina Sultanova, et al.
Published: (2024-12-01)

Real-world study of adverse events associated with triptan use in migraine treatment based on the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS) database
by: Wen-Hui Liu, et al.
Published: (2024-11-01)